Pérez-Lozano U, Tripp-Villanueva F, Ramírez-Alvarado A, Vela-Ojeda J, Limón-Flores A, Kramis-Cerezo JL

Language: Spanish
References: 3
Page: 449-451
PDF size: 41.68 Kb.

ABSTRACT

Background: bone marrow autologous transplantation (BMAT) has proven benefits in patients treated for non-Hodgkin’s lymphoma (NHL). Plerixafor is an inhibitor of CXCR4 receptor. The aim was to report the raise of hematopoietic cells with plerixafor in patients with NHL.
Clinical cases: patient 1 with follicular NHL, GI, intermediate FLIPI, CD20+, CD45+, BCL-2+, who reached complete response after three chemotherapy regimes. Mobilization failed after use of filgrastim (G-CSF) alone and G-CSF + cyclophosphamide. A new attempt was made with G-CSF + plerixafor (G-CSF, 10 µg/kg for 7 days + plerixafor, 240 µg/kg in days 4 to 7). Patient 2 with follicular NHL and CD20+ reached complete remission with MINE after therapeutic failure with other regimes, but develops severe marrow toxicity. Mobilization was supported with G-CSF 10 µg/kg/d + plerixafor in days 4 and 5. In case one, proper cell counts where obtained after three aphaeresis. In the second case, two harvests add of 2.7 × 10⁶/kg were obtained.
Conclusions: plerixafor raised the hematopoietic stem cells in peripheral blood and improves mobilization of proper cell population.

REFERENCES

1. Steinberg M, Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non- Hodgkin’s lymphoma or multiple myeloma. Clin Ther 2010; 32(5):821-843.

2. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112(4):990- 998. Disponible en http://bloodjournal.hematologylibrary. org/content/112/4/990.long

3. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2010;51(5):968-975.